Terms: = Breast cancer AND TET2, Q6N021, MGC125715, KIAA1546, FLJ20032, ENSG00000168769, 54790 AND Treatment
16 results:
1. TET Enzymes and 5hmC Levels in Carcinogenesis and Progression of breast cancer: Potential Therapeutic Targets.
Salmerón-Bárcenas EG; Zacapala-Gómez AE; Torres-Rojas FI; Antonio-Véjar V; Ávila-López PA; Baños-Hernández CJ; Núñez-Martínez HN; Dircio-Maldonado R; Martínez-Carrillo DN; Ortiz-Ortiz J; Jiménez-Wences H
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203443
[TBL] [Abstract] [Full Text] [Related]
2. tet2-mediated epigenetic reprogramming of breast cancer cells impairs lysosome biogenesis.
Laurent A; Madigou T; Bizot M; Turpin M; Palierne G; Mahé E; Guimard S; Métivier R; Avner S; Le Péron C; Salbert G
Life Sci Alliance; 2022 Jul; 5(7):. PubMed ID: 35351824
[TBL] [Abstract] [Full Text] [Related]
3. tet2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling.
Zhang X; Li S; He J; Jin Y; Zhang R; Dong W; Lin M; Yang Y; Tian T; Zhou Y; Xu Y; Lei QY; Zhang J; Zhang Q; Xu Y; Lv L
Cancer Res; 2022 Jun; 82(11):2097-2109. PubMed ID: 35176127
[TBL] [Abstract] [Full Text] [Related]
4. Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian cancer.
Weber-Lassalle K; Ernst C; Reuss A; Möllenhoff K; Baumann K; Jackisch C; Hauke J; Dietrich D; Borde J; Park-Simon TW; Hanker L; Prieske K; Schmidt S; Weber-Lassalle N; Pohl-Rescigno E; Kommoss S; Marmé F; Heitz F; Stingl JC; Schmutzler RK; Harter P; Hahnen E
J Natl Cancer Inst; 2022 Apr; 114(4):565-570. PubMed ID: 34963005
[TBL] [Abstract] [Full Text] [Related]
5. Regulation of tet2 gene expression and 5mC oxidation in breast cancer cells by estrogen signaling.
Zhu X; Xiong L; Lyu R; Shen Y; Liu L; Li S; Argueta C; Tan L
Biochem Biophys Res Commun; 2022 Jan; 589():240-246. PubMed ID: 34929447
[TBL] [Abstract] [Full Text] [Related]
6. tet2 and DNMT3A mutations and exceptional response to 4'-thio-2'-deoxycytidine in human solid tumor models.
Yang SX; Hollingshead M; Rubinstein L; Nguyen D; Larenjeira ABA; Kinders RJ; Difilippantonio M; Doroshow JH
J Hematol Oncol; 2021 May; 14(1):83. PubMed ID: 34039392
[TBL] [Abstract] [Full Text] [Related]
7. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors.
Lei X; Ou Z; Yang Z; Zhong J; Zhu Y; Tian J; Wu J; Deng H; Lin X; Peng Y; Li B; He L; Tu Z; Chen W; Li Q; Liu N; Zhang H; Wang Z; Fang Z; Yamada T; Lv X; Tian T; Pan G; Wu F; Xiao L; Zhang L; Cai T; Wang X; Tannous BA; Li J; Kontos F; Ferrone S; Fan S
Clin Cancer Res; 2021 Jul; 27(13):3757-3771. PubMed ID: 33811153
[TBL] [Abstract] [Full Text] [Related]
8. [Clinical analysis of 12 cases of acute myeloid leukemia complicated with synchronous primary solid tumor].
Mi RH; Dang HB; Chen L; Han YL; Wang MF; Zhang YL; Chen L; Li DB; Wei XD
Zhonghua Yi Xue Za Zhi; 2020 Nov; 100(42):3323-3327. PubMed ID: 33202495
[No Abstract] [Full Text] [Related]
9. miR-660-5p promotes breast cancer progression through down-regulating tet2 and activating PI3K/AKT/mTOR signaling.
Peng B; Li C; He L; Tian M; Li X
Braz J Med Biol Res; 2020; 53(12):e9740. PubMed ID: 33146288
[TBL] [Abstract] [Full Text] [Related]
10. p53-dependent autophagic degradation of tet2 modulates cancer therapeutic resistance.
Zhang J; Tan P; Guo L; Gong J; Ma J; Li J; Lee M; Fang S; Jing J; Johnson G; Sun D; Cao WM; Dashwood R; Han L; Zhou Y; Dong WG; Huang Y
Oncogene; 2019 Mar; 38(11):1905-1919. PubMed ID: 30390073
[TBL] [Abstract] [Full Text] [Related]
11. Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways.
Lyu Y; Lou J; Yang Y; Feng J; Hao Y; Huang S; Yin L; Xu J; Huang D; Ma B; Zou D; Wang Y; Zhang Y; Zhang B; Chen P; Yu K; Lam EW; Wang X; Liu Q; Yan J; Jin B
Leukemia; 2017 Dec; 31(12):2543-2551. PubMed ID: 28400619
[TBL] [Abstract] [Full Text] [Related]
12. IDH2 Mutations Define a Unique Subtype of breast cancer with Altered Nuclear Polarity.
Chiang S; Weigelt B; Wen HC; Pareja F; Raghavendra A; Martelotto LG; Burke KA; Basili T; Li A; Geyer FC; Piscuoglio S; Ng CK; Jungbluth AA; Balss J; Pusch S; Baker GM; Cole KS; von Deimling A; Batten JM; Marotti JD; Soh HC; McCalip BL; Serrano J; Lim RS; Siziopikou KP; Lu S; Liu X; Hammour T; Brogi E; Snuderl M; Iafrate AJ; Reis-Filho JS; Schnitt SJ
Cancer Res; 2016 Dec; 76(24):7118-7129. PubMed ID: 27913435
[TBL] [Abstract] [Full Text] [Related]
13. Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of tet2.
Inoue S; Li WY; Tseng A; Beerman I; Elia AJ; Bendall SC; Lemonnier F; Kron KJ; Cescon DW; Hao Z; Lind EF; Takayama N; Planello AC; Shen SY; Shih AH; Larsen DM; Li Q; Snow BE; Wakeham A; Haight J; Gorrini C; Bassi C; Thu KL; Murakami K; Elford AR; Ueda T; Straley K; Yen KE; Melino G; Cimmino L; Aifantis I; Levine RL; De Carvalho DD; Lupien M; Rossi DJ; Nolan GP; Cairns RA; Mak TW
Cancer Cell; 2016 Aug; 30(2):337-348. PubMed ID: 27424808
[TBL] [Abstract] [Full Text] [Related]
14. Discordant intracellular and plasma D-2-hydroxyglutarate levels in a patient with IDH2 mutated angioimmunoblastic T-cell lymphoma.
Churchill H; Naina H; Boriack R; Rakheja D; Chen W
Int J Clin Exp Pathol; 2015; 8(9):11753-9. PubMed ID: 26617922
[TBL] [Abstract] [Full Text] [Related]
15. Prolonged re-expression of the hypermethylated gene EPB41L3 using artificial transcription factors and epigenetic drugs.
Huisman C; van der Wijst MG; Falahi F; Overkamp J; Karsten G; Terpstra MM; Kok K; van der Zee AG; Schuuring E; Wisman GB; Rots MG
Epigenetics; 2015; 10(5):384-96. PubMed ID: 25830725
[TBL] [Abstract] [Full Text] [Related]
16. The CpG island methylator phenotype: what's in a name?
Hughes LA; Melotte V; de Schrijver J; de Maat M; Smit VT; Bovée JV; French PJ; van den Brandt PA; Schouten LJ; de Meyer T; van Criekinge W; Ahuja N; Herman JG; Weijenberg MP; van Engeland M
Cancer Res; 2013 Oct; 73(19):5858-68. PubMed ID: 23801749
[TBL] [Abstract] [Full Text] [Related]
